Skip to Main Content

Cancer drugs that unleash a patient’s immune system to attack tumors have rapidly won accelerated approval from the Food and Drug Administration. These checkpoint inhibitors have also quickly gained acceptance from oncologists.

That’s the goal of fast-track approval granted by the Food and Drug Administration to Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda — to speed drugs to people who have not found success with other cancer therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • More false hope to shut people up and make money off of the insurance scam. The misery isn’t felt by the ones making the rules to stop pain relief for those who need it. That is, until it happens to them or someone they care about.

Comments are closed.